From GlobeNewswire:

HilleVax, Inc. is set to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 8, 2024 at 4:30 p.m. EST / 1:30 p.m. PST. The company will discuss HIL-214, its investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1. Norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year.

HilleVax’s initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults.

HilleVax urges caution with statements contained in this press release, reminding readers that forward-looking statements regarding matters that are not historical facts are inherently uncertain. The risks and uncertainties inherent in the company’s business include: the success of HIL-214 and the completion of clinical trials, dependence on third parties in connection with manufacturing, research, and clinical and preclinical testing, adverse side effects or inadequate immunogenicity, unfavorable results from clinical trials, market and economic conditions, regulatory developments in the United States and foreign countries, and the company’s reliance on intellectual property rights. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.



Read more: HilleVax to Present at the 42nd Annual J.P. Morgan